Impax Generics

Our Generics Division

View website

Impax has developed a portfolio of generic pharmaceuticals through the internal filing of Abbreviated New Drug Applications (ANDAs) and through partnerships on alternative dosage form products. Our generic product development strategy is based on a combination of speed to filing and a legal strategy primarily predicated upon non-infringement of established brand name pharmaceuticals. We are focused on targeting high-value solid oral and alternative dosage form ANDAs that are difficult to develop and that bring sustainable profitability.

Global’s multi-source product line consists of a growing range of solid oral and alternative dosage form prescription pharmaceuticals, distributed primarily through drug wholesalers, distributors, warehousing chains and managed healthcare organizations.

The organization continues to invest in order to provide the highest level of research and development, manufacturing and customer service. Our quality assurance team works closely with our suppliers to ensure purity, consistency and quality of products, and we strive to bring value to our customers with innovative products in key therapeutic areas.

We have a dedicated team of experienced professionals handling customer orders and inquiries that work to not only meet the expectations of our customers, but consistently deliver beyond expectations. Every member of our team is committed to the success and profitability of our customers. We have set the highest standards for our products, services and people, and are proud of the organization we are building.

We develop, manufacture, sell and distribute generic pharmaceutical products primarily through three sales channels:

  • Product sales channel, for generic pharmaceutical prescription products we sell directly to wholesalers, large retail drug chains, mass merchandisers and mail-order pharmacies
  • Rx Partner sales channel, for generic prescription products sold through unrelated third-party pharmaceutical entities pursuant to alliance agreements
  • OTC Partner sales channel, for sales of generic pharmaceutical OTC products sold through unrelated third-party pharmaceutical entities pursuant to alliance agreements.

Product Development Strategy

Our generic product development strategy is based on two opportunities we've identified in the generic pharmaceutical marketplace:

  • Controlled-Release Generic Products
    Through our controlled-release drug delivery technologies and formulation skills we develop bioequivalent versions of selected brand name pharmaceuticals. Controlled-release pharmaceuticals generally have technically challenging drug delivery requirements. We employ our proprietary processes and formulation expertise to develop products that reproduce the brand name product’s physiological characteristics, but do not infringe upon the brand product’s patents.
  • Specialty Generic Products
    Products that present one or more competitive barriers to entry, such as difficulty sourcing raw material, complex formulation or development characteristics, or special handling requirements.

Our Products

We currently manufacture and market 207 generic pharmaceutical products, which represent dosage variations of 72 different pharmaceutical compounds through our Generics Division; another five of our generic pharmaceutical products representing dosage variations of two different pharmaceutical compounds are marketed by our alliance agreement partners.

Our Pipeline

We currently have more than 20 Abbreviated New Drug Applications (ANDA) pending at the FDA. We are also working on a number of products in various stages of development for which applications have not yet been filed.